Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Q42608504)
Jump to navigation
Jump to search
scientific article published on October 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). |
scientific article published on October 2011 |
Statements
1 reference
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (English)
1 reference
Peter C Thuss-Patience
1 reference
Albrecht Kretzschmar
1 reference
Dmitry Bichev
1 reference
Tillman Deist
1 reference
Axel Hinke
1 reference
Kirstin Breithaupt
1 reference
Yasemin Dogan
1 reference
Bernhard Gebauer
1 reference
Guido Schumacher
1 reference
Peter Reichardt
1 reference
1 October 2011
1 reference
1 reference
47
1 reference
15
1 reference
2306-2314
1 reference
Identifiers
1 reference
1 reference